2.50

7.41% -0.20

Anavex Life Sciences Corp (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corp stock is traded at $2.50, with a volume of 749.39K. It is down -7.41% in the last 24 hours and up +1.63% over the past month. Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Previous Close:

$2.70

Open:

$2.7

24h Volume:

749.39K

Relative Volume:

0.64

Market Cap:

$231.68M

Revenue:

Net Income/Loss:

$-39.95M

P/E Ratio:

-5.3775

EPS:

-0.4649

Net Cash Flow:

$-34.08M

1W Performance:

-9.42%

1M Performance:

+1.63%

6M Performance:

-41.59%

1Y Performance:

-77.64%

1-Day Range:

$2.425

$2.71

1-Week Range:

$2.425

$2.79

52-Week Range:

$2.41

$13.99

Anavex Life Sciences Corp Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corp

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2026-08-11

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corp	2.50	231.68M	0	-39.95M	-34.08M	-0.4649
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corp Stock (AVXL) Latest News

01:40 AM

Trading Systems Reacting to (AVXL) Volatility - Stock Traders Daily

01:40 AM

Jul 07, 2026

AVXL Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock HigherRevenue Growth Outlook - dars.gov.et

Jul 07, 2026

Jul 05, 2026

Anavex Life Sciences (AVXL) Jumps 6.98% as Biotech Rally Tests Key Resistance at $2.90TRIN Signal - dars.gov.et

Jul 05, 2026

Jul 04, 2026

Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks - Sahm

Jul 04, 2026

Jul 01, 2026

CEO transition and delayed SEC filing put Anavex (AVXL) leadership changes in focus - MSN

Jul 01, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jul 01, 2026

How Anavex Life Sciences Corp. (AVXL) Affects Rotational Strategy Timing - Stock Traders Daily

Jul 01, 2026

Jun 30, 2026